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Higher impact of mineral metabolism on cardiovascular mor- We previously investigated the influence of mineral
tality in a European hemodialysis population. metabolism and other variables on mortality in HD pa-
Background. Cardiovascular disease is the main cause of tients [4] and found an influence of calcitriol treatmentmorbidity and mortality among hemodialysis patients. Chronic
and Bsm I polymorphism on all-cause mortality. In therenal failure influences a number of factors that cause acceler-
present study, we have investigated the influence of vari-ated atherogenesis, with calcium, phosphorus, and PTH playing
key roles. Several studies have demonstrated the influence of ables on cardiovascular mortality over six years in HD
these factors on all-cause and cardiovascular mortality in the patients.
American hemodialysis population. In the present study we
evaluated the variables that influence long-term cardiovascular
mortality in a European hemodialysis population. METHODS
Methods. One hundred and forty-three hemodialysis pa-
Patientstients were followed for six years. Several Cox models were
used to study the influence of demographic and biochemical This was a prospective study that began in January
data, and comorbid conditions in cardiovascular survival, with
1996 that included the prevalent hemodialysis (HD) pop-a particular interest in mineral metabolism.
ulation of Lleida, Spain [143 Caucasian patients (80Results. There was an increased risk of cardiovascular death
in patients with serum P 6.5 mg/dL (risk ratio [RR], 2.5), male/63 female; mean age, 61.9 years)]. One hundred
PTH 50 pmol/L (RR, 3.9), Ca x P 52 (RR, 2.8), BB or Bb and fourteen patients were under calcitriol treatment
genotype (RR, 3.8), and in diabetics. the year before initiating the study (0.25 to 0.5 g post-Conclusion. There is a stronger influence of mineral metabo-
HD if iPTH20 pmol/L), with calcium levels below 10.5lism on cardiovascular death among European patients when
mg/dL (2.6 mmol/L) after correcting phosphorus levels.compared to the American population.
If PTH levels fell below 20 pmol/L or the Ca x P product
exceeded 70, calcitriol was stopped. None of the patients
had calcitriol treatment discontinued for more than aPrevious studies in the United States hemodialysis
month. Such patients were considered as calcitriol-(HD) population have shown a relationship between
treated. Calcium compounds were the phosphorus-bind-mineral metabolism and survival in HD patients. The
study by Block [1] shows an elevation in the risk of death ing agents of choice, and aluminum hydroxide was sel-
as serum phosphorus rises. The deleterious effects of an dom used [all patients had serum aluminum levels below
elevated Ca x P product have been widely reported [2, 3]. 40 g/L (1482 nmol/L)]. No patient was receiving any
Although these studies are adjusted for comorbid con- anticonvulsant, steroid, immunosupressant drugs, or vi-
ditions, the heterogeneity of the U.S. population makes tamin D supplements. All patients gave informed con-
their results difficult to extrapolate to the European pop- sent. The follow-up period lasted six years (January 1,
ulation, where social, economic, and ethnic differences 1996 to January 1, 2002).
may have less influence on the outcome. In spite of this,
VDR genotypingthere are no European studies that have investigated the
influence of these variables on the survival of hemodialy- VDR genotyping was performed according to pre-
sis patients. viously described methods [5].
Biochemical and clinical data. Biochemical and clini-
cal data were obtained from the patients’ medical re-Key words: calcitriol, VDR, hemodialysis, Ca x P product, cardiovascu-
lar mortality, hyperparathyroidism, 1,25-dihydroxyvitamin D3. cords. The values included in the analysis were the mean
of the four-monthly determinations recorded during 1995, 2003 by the International Society of Nephrology
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Table 1. Demographic characteristics of the population dividedprior to the start of the study, and obtained before the
according to their cardiovascular outcome (dead of cardiovascular
second HD session of the week. All biochemical determi- cause, not dead of cardiovascular outcome)
nations were performed at the same laboratory using
CV Non CV Pmethods previously described [4].
N 35 108Cardiovascular fatal events were the end points and
Sex M/F 20/15 60/48 NS
included myocardial infarction, cerebrovascular acci- Age years 66.7 60.4 NS
ESRD etiologydent, ischemic perypheric vascular disease, and sudden
Vascular 5 (14.3%) 6 (5.6%) NSdeath [6]. Glomerular 2 (5.7%) 15 (14%) NS
Statistical analysis. Chi-square and analysis of vari- Interstitial 4 (11.4%) 22 (20.6%) NS
PKD 5 (14.3%) 13 (12.1%)ance (ANOVA) were used to compare variables between
Diabetic 9 (25.7%) 18 (16.8%) NSthe patients who had died from cardiovascular conditions Other 10 (23.3%) 33 (30.8%) NS
and those who had not. bb genotype 8 (22.8%) 43 (39.8%) NS
Hours of HD per week 12 12 NSThree models of Cox were used to estimate the rela-
Calcitriol treatment 25 (71.4%) 88 (81%) NStionship between cardiovascular death and variables. Hepatitis C virus 11 (31%) 29 (26.8%) NS
Smoking habit yes/no/ex 4/20/11 12/60/30 NSModel 1 included adjustments similar to Block’s [1], (age,
History of high blood pressure 6 (17.1%) 18 (16.6%) NSgender, smoking habit, diabetes, and serum phosphorus),
Time on HD days 1754 1650 NS
with serum phosphorus as a continuous variable. Model Diabetes 11 (31.4%) 18 (16.6%) NS
Ca x P mg2/dL2 54.4 54.2 NS2 included the same adjustments, with phosphorus as a
PTH pmol/dL 25.5 25.6 NSqualitative variable that divided patients into two groups
Albumin g/dL 3.9 4 NS
above or below 6.5 mg/dL (2.1 mmol/L). The chosen cut-
Tests performed were ANOVA and 2. Abbreviations are: CV, patients who
off point was 6.5 because previous large studies have died from cardiovascular causes; Non CV, patients who did not die from cardio-
vascular causes (alive, transplanted, or dead from other causes).demonstrated that this is the value above which mortality
significantly increases in HD patients [1]. Model 3 was
adjusted for age (in days), gender, Ca x P product (52
or52), PTH group, Bsm I genotype (BB or Bb vs. bb), Table 1 shows the demographic, clinical, and biochem-
calcitriol, albumin, hours of HD per week, time on HD, ical characteristics of the population studied. No signifi-
smoking habit (smoker, ex-smoker, non smoker), diabe- cant differences were found between those who died
tes mellitus, hepatitis C antibodies, pre-HD blood pres- from cardiovascular reasons and those who did not.
sure (120/75, 120 to 160/75 to 90, or 160/90 mm Hg), When cardiovascular mortality was adjusted for gen-
and history of hypertension. Fifty-two was chosen as the der, age, diabetes, smoking habit, and phosphorus, Cox
cut-off point for the Ca x P product based on recent analysis showed that diabetes and phosphorus increase
studies which have demonstrated an increase of mortality the risk of cardiovascular death. When phosphorus was
in HD patients above this value [7]. For similar reasons, entered as a qualitative variable age, diabetes and phos-
PTH was entered as a qualitative variable. It is consid- phorus 6.5 were found significant. When adjustments
ered that the patients with extreme values might be at were made for all comorbid conditions and biochemical
an increased risk of cardiovascular calcifications. Thus, data, the following variables were found significant: Ca
PTH was entered as a categorical variable and the pa- x P 52, BB or Bb genotype, PTH 50 pmol/L vs. 12
tients were assigned to one of the following groups: “low” to 50 pmol/L, and diabetes (Table 2).
PTH group (12 pmol/L), “medium” PTH group (12 to Figure 1A shows cardiovascular survival throughout
50 pmol/L), and “high” PTH group (50 pmol/L). the six years of follow-up according to PTH group and
In order to minimize bias caused by the transversal adjusted for covariables by Cox analysis. In the interme-
nature of the study, previous time on HD was included diate PTH group, more patients remained free from car-
as one of the variables in the Cox analysis. Patients were diovascular death after six years, a significant difference
censored (that is, removed from the analysis) at the time when compared with the group with PTH476.1 pg/mL
of transplantation, or if they died from reasons other (50 pmol/L) (P  0.02). Figure 1B represents cardiovas-
than cardiovascular events. cular survival for the two Ca x P groups (P  0.03).
RESULTS DISCUSSION
After six years of follow-up, 35 patients (24.4%) had Cardiovascular events are the most frequent cause of
died from cardiovascular causes. Nineteen patients death among end-stage renal disease (ESRD) patients
(13.2%) had been transplanted, 50 (34.9%) died for rea- in all populations. Previous studies have shown a rela-
sons other than cardiovascular events, and 39 (27.2%) tionship between poor phosphorus control and cardiac
and vessel calcifications, which lead to cardiovascularremained alive and on HD.
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Fig. 1. Survival adjusted for variables in Cox
analysis through the six years of follow-up
for patients according to PTH (A) and P (B)
group. Conversion factor for P is 0.3229; for
PTH is 0.105.
Table 2. Relative risk for cardiovascular mortality associated spite of this, this is the first study to show the stronger
with the selected covariables in Cox analysis
influence of phosphorus and Ca x P product control
Variable P Exp(B) (95% CI) in the incidence of fatal cardiovascular events in our
Model I population. Like the U.S. ESRD population [7], this
Age days 0.01 1.03 (1.008–1.07) study suggests that the current treatment of hyperphos-
Phosphorus mg/dL 0.03 1.2 (1.01–1.5)
phatemia should be more ambitious and the Ca x P levelDiabetes 0.00 2.7 (1.2–6)
Model II should be below 52.
Age days 0.02 1.003 (1.005–1.06) In this study, raised PTH levels also emerged as a
Phosphorus 6.5 mg/dL 0.01 2.5 (1.2–5.2)
cardiovascular mortality marker. Unlike Block’s study,Diabetes 0.00 2.8 (1.2–6.1)
Model III the presence of severe hyperparathyroidism [defined as
BsmI genotype Bb or BB 0.00 3.8 (1.5–9.6) PTH levels above 476.1 pg/mL (50 pmol/L)] increases
Ca x P 52 0.03 2.8 (1.1–7.1)
the risk of suffering a fatal cardiovascular event fourfold.PTH 50 pmol/L (vs. 12 to 50) 0.02 3.9 (1.2–12.9)
Diabetes 0.01 3.2 (1.2–7.9) In line with our results, a recent U.S. study [8] showed
Adjustments were made for the following covariables: Model I: age, gender, a relationship between PTH 495 pg/mL and sudden
diabetes, smoking habit and serum phosphorus (non-categorical); Model II: age, death, although this could not be demonstrated for othergender, diabetes, smoking habit, and serum phosphorus (categorical:6.5 mg/dL,
6.5 mg/dL); Model III: Bsm I (bb vs. no bb), calcitriol treatment, Ca x P types of cardiovascular events.
product (52, 52), PTH (12 pmol/L, 12 to 50, 50 pmol/L, albumin, sex, Lower PTH levels [65 pg/mL (6.8 pmol/L)] have alsoage, diabetes, hepatitis C antibodies (VHC), time on HD, hours of HD/week,
history of smoking, predialysis blood pressure, and history of hypertension. The been associated with shorter survival time in HD patients
conversion factor for P is 0.3229 and for PTH is 0.105. [9, 10]. This has been interpreted as a marker of malnutri-
tion and is in keeping with the numerous studies that
relate markers of malnutrition with higher mortality. Our
patients with lower PTH levels showed poor survivalevents [2, 3]. Yet, different renal data registers suggest
times, although they did not reach statistical significancea different profile of European ESRD patients with re-
(Fig. 1).spect to the U.S. HD population. In particular, the Case
This study arouses the current limitations of hyper-Mix Adequacy Study (CMAS) from the USRDS shows
parathyroidism treatment. On one hand, high PTH levelsthat 30% of patients have serum P above 7 mg/dL (2.24
should be avoided. On the other hand, the use ofmmol/L) and around 10% have serum P greater than 9
calcitriol and calcium-based phosphate binders is associ-mg/dL (2.8 mmol/L) [1], whereas only 18% and 2% of
ated with an increase in the Ca x P product and soft tissueour patients surpassed such levels.
calcifications. The introduction of new non-calcium non-Other differential characteristics of our patients are
aluminum phosphate binders [11, 12] has been usefulthe lower prevalence of diabetes mellitus (20% vs. 30%
but the presence of intolerance and acidosis limits theirin the U.S.) [1] and the presence of less marked differ-
use [13, 14]. Administration of these phosphate bindersences in ethnic, social, cultural, and economic factors.
in the predialysis period, which would be desirable inThere is higher treatment compliance, and attendance
order to start early treatment of the phosphate imbal-rate for HD sessions, for instance, is exceptional. Thus,
ance, has not been safely established.in general, our population is more homogeneous than
In the same way, less hypercalcemic vitamin D deriva-that of the U.S.; this fact could make other variables
hold more weight in the prognosis of the patients. In tives are already in use [15, 16], but there is not enough
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